NanoString Technologies Inc.: NanoString Technologies to Release Second Quarter 2015 Financial Results and Host Conference Call on Tuesday, August 4, 2015

Tickers: NSTG
SEATTLE, July 21, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release second quarter 2015 financial results after the close of trading on Tuesday, August 4, 2015. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.

Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers, or from the webcast link in the investor relations section of the company's website at:

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
International Business Machines Corporation
A replay of the call will be available beginning August 4, 2015 at 7:30pm ET through midnight on August 5, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 73609652. The webcast will also be available on the company's website for one year following the completion of the call.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 700 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has also been applied to diagnostic use. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

For more information, please visit

CONTACT: Investor Contact:

         Leigh Salvo of Westwicke Partners

         For NanoString

Source: NanoString Technologies, Inc.

News Provided by Acquire Media

distributed by

This content was issued by NanoString Technologies Inc. on the 2015-07-21 and was initially posted on It was distributed, unedited and unaltered, by noodls on 2015-07-21 20:17:18 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.